White Paper

In-House Versus Outsource: A Decision-Making Guide

By B. Rosenblatt, Ph.D., SME Biotech Consulting and D. Kenyon, Ph.D., Thermo Fisher Scientific

Decision

The biologics market is quickly evolving from a focus on developing blockbuster drugs to exploring niche markets with unmet needs. While the changes are exciting, they pose several risks to a molecule’s success as competition intensifies, timelines shorten and capacity challenges emerge. Yesterday’s solutions may not be a perfect fit for today’s molecules.

Given this backdrop, biopharmaceutical companies are increasingly looking  for new strategies to bring biologics to market quickly and cost effectively. Companies must carefully assess whether their in-house teams can truly deliver everything a project needs to be successful-from accurate supply forecasting  to successful IND submission to meeting aggressive timelines. In doing so, biopharmaceutical executives must consider how outsourcing fits into their development and production strategy, as well as how to select the best  CDMO partner for their business.

VIEW THE WHITE PAPER!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of BioProcess Online? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: